Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" ...

Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Shares of Merck are sliding in early trading after ... due partly to a pause in shipments of one of its top-selling products to China Shares of Merck slid Tuesday after the drugmaker surprised ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.